Navigation Links
Angiotech and Rex Medical announce exclusive licensing and distribution agreement for the "Option(TM)" inferior vena cava filter
Date:3/13/2008

VANCOUVER, March 13 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) announced today that it has entered into a definitive licensing agreement with privately held Rex Medical, LP ("Rex Medical") for exclusive worldwide rights to market and distribute the Option(TM) inferior vena cava (IVC) filter, a medical device that is implanted into the body's inferior vena cava to prevent pulmonary embolism (PE).

According to industry research, the U.S. market for IVC filters in 2007 was approximately $200 million with retrievable filters accounting for approximately two-thirds of this market. The Option(TM) IVC filter, developed by Rex Medical, is an IVC filter specifically designed for long-term retrieval post device implantation and is expected to be approved for both permanent and retrievable indications.

Angiotech and Rex Medical will be exhibiting at the 33rd Annual Meeting of the Society of Interventional Radiology (SIR) to be held in Washington, DC from March 15-18, 2008.

"With product offerings such as the Option(TM) IVC filter and our EnSnare(TM) retrieval device, we are continuing our commitment to offer industry-leading technologies to service the needs of our interventional and endovascular call points. We believe that the Option(TM) IVC filter is a cornerstone technology for our Interventional business and a 'best-in-class' product that will be significantly differentiated in the marketplace," said Dr. William Hunter, President and CEO of Angiotech.

"We are pleased to have entered into this commercial partnership with Angiotech for the Option(TM) IVC filter in such a critical market for the interventional community. We believe that the Option(TM) IVC filter is a superior IVC f
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Angiotech showcases its Hemostream(TM) Dialysis Catheter at the Society of Interventional Radiology (SIR) Annual Meeting
2. Angiotech announces results for the fourth quarter ended December 31, 2007
3. Angiotech to participate in Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
4. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
5. Angiotech and Symphony Medical Announce Licensing Agreement
6. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
7. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
8. Angiotech to participate in RBC 2007 Healthcare Conference
9. Angiotech to participate in Bank of America 2007 Credit Conference
10. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
11. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... YORK , July 29, 2014  Pomerantz LLP ... Laboratories, Inc. ("Impax" or the "Company") (NASDAQ: IPXL).  Such ... at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. ... of its officers and/or directors have violated Sections 10(b) ... On July 29, 2014, Impax Laboratories, ...
(Date:7/29/2014)... According to the new research ... (Image Analysis Software), Delivery Modes (Web Based/Cloud Based) & ... to 2018", published by MarketsandMarkets, analyzes and studies the ... North America , Europe ... Rest of the World (RoW). Browse 78 ...
(Date:7/29/2014)... , July 29, 2014 /PRNewswire-iReach/ -- Nanosyn, ... with FORMA Therapeutics, Inc., to provide access to ... fragment-based lead discovery platform for novel small molecule ... about the opportunity to work with FORMA Therapeutics ... epigenetics and protein homeostasis. FORMA Therapeutics, decision to ...
(Date:7/29/2014)... , July 29, 2014  Cannabis Science, ... cannabis formulation-based drug development and related consulting, applauds ... for taking a strong position in opposition to ... July 27, 2014 publication.  The New York Times ... articles this week exploring the issue called "High ...
Breaking Biology Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories, Inc. - IPXL 2Digital Pathology Market worth $437 Million by 2018 2Digital Pathology Market worth $437 Million by 2018 3Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 3
... Call Today at 4:30 p.m. Eastern Time - SAN FRANCISCO, March ... today reported on its corporate progress and financial results ... a very productive 2008 and are looking forward to an equally ... are on track to be in Phase 3 testing in all ...
... announces that its lead compound for inhibition of tau ... has been recognized as the most potent inhibitor of ... to date. Mutations of this gene are believed ... frequent cause of Parkinson,s Disease.TauTaTis, lead compound is a ...
... Traceability Down to the Unit Level to Secure Products and ... ... Southborough, MA (PRWEB) March 16, 2009 -- PHARMORX Security™, a ... provider, today announced the availability of its new comprehensive technology ...
Cached Biology Technology:Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update 2Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update 3Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update 4Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update 5Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update 6Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update 7Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update 8TauTaTis Discovers Potent Inhibitor of Parkinson's Disease Gene Activity 2PHARMORX Security Introduces New Technology Solutions for Counterfeiting, Grey Market Diversion, Track & Trace 2PHARMORX Security Introduces New Technology Solutions for Counterfeiting, Grey Market Diversion, Track & Trace 3
(Date:7/29/2014)... Helping people recover from the debilitating effects of ... requires deep knowledge of neurophysiology as well as ... options and outcomes has been the primary focus ... biomedical engineering, since he joined the NJIT faculty ... whose significance is underscored by substantial funding from ...
(Date:7/29/2014)... Dentistry (UM SOD) and Medicine (UM SOM) jointly ... $10.7 million grant award from the National Institute ... National Institutes of Health to study the causes, ... grant, which renews a previous $12 million five-year ... the research by studying chlamydial and gonorrheal diseases ...
(Date:7/29/2014)... brings together two of the major disciplines behind Jurassic ... fossils through stunning photographs and unique illustrations. , Fossil ... details the incredible preservation and diversity of fossilised insects ... these remarkable fossils can tell us about the ancient ... planet. Like the mosquito in Jurassic Park, many of ...
Breaking Biology News(10 mins):Continuing the quest for better stroke therapies 2Continuing the quest for better stroke therapies 3University of Maryland Schools of Dentistry and Medicine receive NIH grant 2University of Maryland Schools of Dentistry and Medicine receive NIH grant 3University of Maryland Schools of Dentistry and Medicine receive NIH grant 4Unique images bring fossil insects back to life 2
... ecosystem below an Antarctic glacier and learned that it survived ... growth. Described in the April 17 issue of ... a pool of brine trapped below Taylor Glacier and next ... Priscu , co-author of the Science article. Priscu ...
... over, Y chromosome it,s time X got some ... chromosome associated with being female, University of California, Berkeley, ... history of the X chromosome is every bit as ... important clues to the origins and benefits of sexual ...
... Sven Enerbck, Professor at the Institute of Biomedicine at the ... scientists who published their results in The New England ... Enerbck and others show that adults use brown fat to ... new possibilities in treating overweight and obesity. It has ...
Cached Biology News:Ancient ecosystem thrives millions of years below Antarctic glacier 2The story of X -- evolution of a sex chromosome 2The story of X -- evolution of a sex chromosome 3The story of X -- evolution of a sex chromosome 4
... (100+kb), fosmid (40kb), and large plasmid insert ... othe BAC vector. On command 20-50 fold ... recombinant DNA purification. Available with blue-white screening ... for the highest insert stability. Kits include ...
MAGP-2 (C-19)...
... ZMD.473. Immunogen: Synthetic peptide derived ... mouse junctophilin-2. Specificity: Specific for ... (positive controls: mouse skeletal muscle homogenates ... Applications: Western blotting Immunohistochemistry(froz) ImmunofluorescenceStorage: Store ...
TGF-beta 2 MAb (Clone 8607)...
Biology Products: